Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences
REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences.
BTIG 3rd Annual Ophthalmology Day
Format: Fireside Chat
Ashvattha’s Co-Founder, President, and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings. If you are interested in a meeting, please contact your BTIG representative.>
Format: Corporate Presentation
Register for the summit here.
About Ashvattha Therapeutics
Metaverse / Emerging Technologies
The Role of Endpoints in Shaping Future of Work